Market Research Logo

Global Glaucoma Treatment Market - Trends And Opportunities: 2015 Edition

Global Glaucoma Treatment Market - Trends And Opportunities: 2015 Edition

Scope of the Report

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2015 Edition)” analyzes the potential opportunities, challenges, demand drivers and significant trends representing the Glaucoma treatment market. The report elucidates facts on the glaucoma treatment market as supplemented by the latest available statistics. It also profiles and analyzes the leading four companies operating in this industry with latest data and a brief overview of their business and financial performance along with a brief discussion of their future business strategies. The report gives valuable insight into technology used in glaucoma treatment market, its demand in various geographies. In the report, we also try to study the growth pattern in the prescriptions and revenue earned by the glaucoma treatment companies and the latest trends concerning glaucoma treatment market. Most importantly, we have analyzed the current market size and project future market size of the overall glaucoma treatment market for the years to come.

Company Coverage

Biolite Israeli
Pfizer Inc.
Merck & Co. Inc.
Alcon ( A division of Novartis)

Products Covered

Prostaglandin
Combination Market
Carbonic Anhydrase Inhibitor
Beta Blocker
Alpha Agonist & Cholinergic
Surgical Devices

Executive Summary

The global Glaucoma market has been growing rapidly since the past several years mainly due to innovation such as introduction of IOPtiMa, OTP-TX, anti-VEGF therapy, photodynamic therapy (PDT) laser photocoagulation, Rhopressa, latanoprost and Vesneo. Among the several varieties of drugs and surgeries available in the market, the demand for drugs such as Prostaglandins which includes Trabatan, Lumbigan are the highest due to its high efficiency in treating glaucoma. Vesneo has shown a superior intraocular pressure reduction effect on beta-blocker timolol, the most widely used comparator in registration trials for glaucoma, in two phase 3 studies.

Globally, the major factors contributing to the growth of Glaucoma treatment market is the higher number of glaucoma patients from the U.S, Europe and Japan. Novel therapies for glaucoma are constantly being investigated by research and development teams of various pharmaceutical companies, at different stages. It can be predicted that novel therapies that work in conjunction with current drugs, such as Prostaglandins, will likely be increasingly common in the near future.

Growth of the Glaucoma treatment market could also be attributed to North America where the number of patients suffering from glaucoma is the highest among the rest of the U.S and also from emerging markets such as France and Singapore driven by rapid increase of old age population. Moreover, the Asian market is expected to become a huge potential market for glaucoma surgery devices in the foreseeable future, as it is expected to grow at comparatively the fastest among all other regions. It is estimated that by 2020, 11 million individuals will have vision loss due to glaucoma.

Glaucoma market is seen as a diversifying risk to other lines of ophthalmic treatment business and is attracting more and more revenue. Glaucoma treatment companies are launching new technologies and adopting new strategies in the industry and making significant investments.


1. Executive Summary
2. Glaucoma: A Cause for Vision Loss
2.1 Overview
Table 1: Diagrammatic Representation of a Normal Eye
Table 2: Diagrammatic Representation of Developing Glaucoma
Table A: List of Tests for Glaucoma Detection
2.2 Types of Glaucoma
Table 3: Diagrammatic Representation of Open Angle Glaucoma
Table 4: Diagrammatic Representation of Angle Closure Glaucoma
2.3 Prevention and Treatment of Glaucoma
Table 5: Diagrammatic Representation of Argon Laser Trabeculoplasty
Table 6: Diagrammatic Representation of Selective Laser Trabeculoplasty
Table 7: Diagrammatic Representation of Laser Iridotomy
Table 8: Diagrammatic Representation of Trabeculectomy
Table 9: Diagrammatic Representation of Drainage System Surgery
3. Global Glaucoma Treatment Market: Size and Growth
Table 10: Global Glaucoma Treatment Market-(US$ Million)-2012-2014
Table 11: Total Number of Prescriptions issued Worldwide for Glaucoma Treatment-(Million)-2012-2014E
Table 12: Global Glaucoma Treatment Market-(US$ Million)-2015-2019
Table 13: Total Number of Prescriptions forecasted to be issued Worldwide for Glaucoma Treatment-(Million)-2015-2019
4. Glaucoma Market: Regional/Country Analysis
4.1 U.S Glaucoma Treatment Market Analysis: Size and Growth
Table 14: U.S Glaucoma Treatment Market-(US$ Billion)-2012-2014E
Table 15: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2012-2014E
Table 16: U.S Glaucoma Treatment Market Forecast-(US$ Billion)-2015-2019
Table 17: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2015-2019
4.2 U.S Glaucoma Treatment Market Analysis: By Drugs
Table B: List of Drugs Used in U.S Glaucoma Treatment Market-(2013)
4.2.1 U.S Prostaglandin Market Size Segmentation: An Analysis
Table 18: U.S Prostaglandin Market-(2012-2013)
Table 19: U.S Trabatan Market-(2012-2013)
Table 20: U.S Lumbigan Market-(2012-2013)
4.2.2 U.S Combination Market Size Segmentation: An Analysis
Table 21: U.S Combination Market-(2012-2013)
Table 22: U.S Cosopt Market-(2012-2013)
Table 23: U.S Combigan Market-(2012-2013)
4.2.3 U.S Carbonic Anhydrase Inhibitors Market Size Segmentation: An Analysis
Table 24: U.S Carbonic Anhydrase Inhibitors Market-(2012-2013)
Table 25: U.S Carbonic Anhydrase Inhibitor Branded Market-(2012-2013)
4.2.4 U.S Beta Blocker Market Size Segmentation: An Analysis
Table 26: U.S Beta Blocker Market-(2012-2013)
Table 27: U.S Beta Blocker (Branded) Market-(2012-2013)
4.2.5 U.S Alpha Agonist and Cholinergic Market Size Segmentation: An Analysis
Table 28: U.S Alpha Agonist and Cholinergic Market-(2012-2013)
Table 29: U.S Alphagan Market-(2012-2013)
4.3 U.S Vesneo (Glaucoma) Market: An Analysis
Table 31: Expected Prevalence of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020
Table 32: Expected Prescriptions of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020
4.4 U.S Glaucoma Surgical Devices Market: An Analysis
Table 33: U.S Glaucoma Surgical Devices Market-(US$ Billion)-2012-2014E
4.5 Europe7 Vesneo (Glaucoma) Market: An Analysis
Table 34: Expected Prevalence of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
Table 35: Expected Prescription of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
4.6 Japan Glaucoma Treatment Market: An Analysis
Table 36: Japan Glaucoma Treatment Market-(US$ Million)-20112-2014E
4.7 Japan Glaucoma Treatment Market Analysis: By Drugs
Table 37: Japan Glaucoma Drug Treatment Market-(US$ Million)-2010-2013
4.7.1 Tapros Market Size: An Analysis
Table 38: Japan Tapros Market-(US$ Million)-2010-2013
4.7.2 Cosopt Market Size: An Analysis
Table 39: Japan Cosopt Market-(US$ Million)-2010-2013
4.8 Japan Vesneo (Glaucoma) Market: An Analysis
Table 40: Expected Prevalence of Vesneo in Japan-(Million)-2015-2020
Table 41: Expected Prescriptions of Vesneo in Japan-(Million)-2015-2020
5. Global Glaucoma Market Share: An Analysis
Table 42: Global Glaucoma Market Share-(By Region)-2013
5.1 U.S Glaucoma Treatment Market Share: An Analysis
Table 43: Break-Up of U.S. Glaucoma Treatment Market-(By Treatment Types)-2013
Table 44: Break-Up of Glaucoma Treatment Market-(By Drug Types)-2013
Table 45: Break-Up of Prostaglandin Market for Glaucoma Treatment-(2013)
Table 46: Break-Up of Combination Market for Glaucoma Treatment-(2013)
Table 47: Break-Up of Carbonic Anhydrase Market for Glaucoma Treatment-(2013)
Table 48: Break-Up of Beta Blocker Market for Glaucoma Treatment-(2013)
Table 49: Break-Up of Alpha Agonist and Cholinergic Market for Glaucoma Treatment-(2013)
5.2 Japan Glaucoma Treatment Market Share: An Analysis
Table 50: Japan Glaucoma Market Share-(By Treatment Types)-2013
Table 51: Japan Glaucoma Market Share-(By Drug Types)-2013
6. Market Dynamics: Global Glaucoma Market
6.1 Growth Drivers
6.1.1 Innovation
Table 52: Fluid Percolation through Fluid Intact Thinned Sclera by IOPtima
6.1.2 Rising Old Age Population
Table 53: Rising Global Old Age Population-(Billion)-1990-2035E
6.1.3 Rising Global Healthcare expenditure
Table 54: Global Healthcare Expenditure-(US$ Trillion)-2009-2013
6.1.4 Alternative Drug Delivery Methods to Treat Glaucoma
Table C: List of Alternative Drug Delivery Methods to Treat Glaucoma
6.2 Challenges
6.2.1 Vision Loss and Bleeding from Eye
6.2.2 Infection
6.2.3 Side Effects of Glaucoma Drugs
6.3 Market Trends
6.3.1 Anti-VEGF Market Opportunity will continue to Expand
6.3.2 New Glaucoma Drugs to Accelerate Glaucoma Treatment Market
6.3.3 Glaucoma Treatment Ideal for Treating TB
6.3.4 Glaucoma being the second largest reason for blindness
6.3.5 New Treatments to Reduce Intra Ocular Pressure to Treat Glaucoma
6.3.6 Prostaglandin Drugs Most Popular For Glaucoma Treatment
Table 56: Break-Up of Eye Drop Types for Glaucoma Treatment-(By Popularity)
7. Competitive Landscape: Global Glaucoma Market
World’s leading companies and their comparative analysis
Table 55: Market share of leading companies in Glaucoma Treatment-(Surgical Devices)-2013
8. Company Profiles: Global Glaucoma Market
8.1 Biolight Israeli
8.1.1 Business Overview
8.1.2 Financial Overview
Table 56: Biolight Israeli Consolidated Revenue-(US$ Million)-2011-2014
Table 57: Biolight Israeli Revenue Break-up-(Sector)-2014
Table 58: Biolight Israeli Revenue Break-up-(Sector)-2013
8.1.3 Business Strategies
Table 59: Expenses in Research and Development- (US$ Million)-2011-2014
8.2 Pfizer Inc.
8.2.1 Business Overview
8.3.2 Financial Overview
Table 60: Pfizer Revenue from Xalatan and Xalacom-(US$ Million)-2012-2014
Table 61: Pfizer Consolidated Net Income-(US$ Million)-2012-2014
8.3.3 Business Strategies
8.3 Merck & Co. Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
Table 62: Merck & Co. Revenue of Cosopt/Trusopt-(US$ Million)-2012-2014
Table 63: Consolidated Net Income-(US$ Billion)-2012-2014
8.3.4 Business Strategies
8.4 Alcon (A division of Novartis)
8.4.1 Business Overview
8.4.2 Financial Overview
Table 64: Alcon Consolidated Revenue-(US$ Million)-2011-2014
Table 65: Alcon Revenue Break-Up by Franchises-(Percentage)-2013
Table 66: Alcon Revenue Break-Up of Ophthalmic Pharmaceuticals-(Percentage)-2013
Table 67: Alcon Revenue Break-Up by Franchises-(Percentage)-2014
8.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report